Mr. Lynn D. Torbeck - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Mr. Lynn D. Torbeck


Mr. Lynn D. Torbeck is a Pharmtech editorial advisory board (EAB) member

Mr. Lynn D. Torbeck
Principal Statistician
Torbeck & Associates

Lynn D. Torbeck is a consultant specializing in applied statistics and experimental design for pharmaceutical and biopharmaceutical development, quality assurance and control, validation, and production under the CGMPs. Areas of expertise include quality by design, design space, OOS, SQC/SPC, statistical PAT, assay validation, sampling plans, and setting specification criteria. Torbeck has been active in the pharmaceutical industry in statistics, quality, and management since 1975; he has been president of Torbeck and Assoc., Inc. since 1988. He has worked with a wide variety of companies, including pharmaceuticals, biotechnology, fine chemicals, medical devices, and cosmetics. Torbeck is the author of several books on validation and has published a number of journal articles.

Torbeck has been a member of the Editorial Advisory Board of Pharmaceutical Technology since 1999, and was elected to the PDA Scientific Advisory Board (SAB) in 2002 and the USP Statistics Expert Committee for a second five-year term in 2005. He was chair of the PDA’s SAB Out-Of-Specification committee. He won the PDA TRI Excellence in Teaching Award in 1997 and again in 2007. He is also a member of the ASTM E-11, statistics, and E-55, PAT, committees.

Torbeck is a member of the American Statistical Association, PDA, Senior Member of the American Society for Quality, ASQ, ASTM, and is past president of the Chicago Chapter of the American Statistical Association. He is a past Book Reviews Editor for the Journal of Quality Technology, a publication of the American Society for Quality. He holds an AAS degree in Electronics and BS and MS degrees in Statistics with minors in Operations Research and Computer Science.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
9%
All of the above.
45%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing

Click here